Assessment of the presence and prevalence of HIV-2 antibodies in patients attending the Universal College of Medical Sciences Teaching Hospital, Bhairahawa, western Nepal was done. A total of 1534 patients sera were screened for the presence of HIV-1 and HIV-2 antibodies from March 2000 to May 2003. A total of 3 (0.2%) patients were found to be sero-positive for HIV-2 antibodies. Out of the above three patients, 1 (0.1%) was infected with HIV-2 only and the remaining 2 (0.1%) were infected with HIV-1 and HIV-2 both. This evidence of the presence of HIV-2 presence implicates serious outcomes as HIV-2 has not been reported from hospital patients in Nepal.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the MAGLUMI HIV Ab/Ag combi test for the detection of HIV infection.
Virol J
November 2024
Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing, 210009, People's Republic of China.
Background: Human immunodeficiency virus (HIV) infection screening and diagnosis are critical to control the HIV epidemic. Testing for anti-HIV antibodies (Ab) and antigens (Ag) in blood samples is the first step to screen people who have been potentially exposed to the virus. This study aimed to evaluate the performance of the MAGLUMI HIV Ab/Ag Combi for detection of HIV antibodies and antigens.
View Article and Find Full Text PDFHepatitis E virus prevalence among HIV-2 infected individuals in central Portugal.
Eur J Clin Microbiol Infect Dis
December 2024
CERES, University of Coimbra, Coimbra, Portugal.
To date, no studies comparing the prevalence of hepatitis E virus (HEV) infection between the general and human immunodeficiency virus 2 (HIV-2) populations are available. With the purpose of filling this gap, this prevalence was assessed in the HIV-2 population from central Portugal. HEV seropositivity was 19.
View Article and Find Full Text PDFPerformance evaluation of the new Access HIV Ag/Ab combo assay on the DxI 9000 Access Immunoassay Analyzer.
J Clin Virol
October 2024
CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France; Univ Rouen Normandie, Univ de Caen, INSERM, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France. Electronic address:
Fourth-generation HIV immunoassays have been developed to reduce the window period of detection during seroconversion period, allowing for the detection of early and established infections. The aim of this work was to evaluate a newly developed assay, Access HIV Ag/Ab combo on the novel high throughput DxI 9000 Access Immunoassay Analyzer (Beckman Coulter, Inc.).
View Article and Find Full Text PDFMosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Infect Dis
November 2024
Janssen Research & Development, Titusville, NJ, USA.
Background: HIV type 1 (HIV-1) remains a global health concern, with the greatest burden in sub-Saharan Africa. Despite 40 years of research, no vaccine candidate has shown durable and protective efficacy against HIV-1 acquisition. Although pre-exposure prophylaxis in groups with high vulnerability can be very effective, barriers to its use, such as perceived low acquisition risk, fear of stigma, and concerns about side-effects, remain.
View Article and Find Full Text PDFEvaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis.
Microbiol Spectr
July 2024
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Unlabelled: Detection of HIV infection may be challenging in persons using long-acting cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) due to viral suppression and reduced/delayed antibody production. We evaluated two point-of-care tests for detecting HIV infection in persons who received CAB-LA in the HPTN 083 trial. Samples were obtained from 12 participants who received CAB-LA and had delayed detection of HIV infection using HIV rapid tests and an antigen/antibody test (52 plasma samples; 18 dried blood spot [DBS] samples).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!